Personalized Acromegaly Treatment and Management System

A next-generation system for treating acromegaly, leveraging AI-driven dosing algorithms, wearable biosensors, and nanoparticle-based oral formulations to provide personalized, real-time treatment and remote patient monitoring.

The original patent, 'Method of treating diseases,' relates to oral drug delivery of octreotide for treating diseases, specifically acromegaly. However, this approach has limitations, including fixed dosing regimens, variable patient responses, and lack of real-time monitoring. The new inventive concept addresses these limitations by introducing a personalized, adaptive, and connected system for acromegaly treatment and management.

The system comprises a wearable biosensor for monitoring GH and IGF-1 levels, a personalized AI-driven dosing algorithm for optimizing octreotide delivery based on real-time patient data, and a nanoparticle-based oral formulation for targeted release of octreotide in the gut. The system also includes a digital health platform for remote patient monitoring and personalized acromegaly care, featuring a mobile app for tracking symptoms, medication adherence, and lab results, and a cloud-based analytics engine for identifying high-risk patients and providing personalized interventions. A closed-loop acromegaly treatment system is also envisioned, incorporating a subcutaneous implantable device for continuous octreotide delivery and a feedback loop for adjusting dosing based on real-time GH and IGF-1 level monitoring.

The new claims introduce a paradigm shift in acromegaly treatment by integrating AI-driven dosing algorithms, wearable biosensors, and nanoparticle-based oral formulations. These innovations provide a personalized, adaptive, and connected system that overcomes the limitations of fixed dosing regimens and variable patient responses, thereby offering a novel and non-obvious approach to acromegaly treatment and management.

Alternative embodiments of the inventive concept could include using different types of biosensors, such as implantable or ingestible sensors, or incorporating additional data sources, such as genetic profiles or medical histories, to further personalize treatment plans. Variations of the system could also include different nanoparticle-based formulations or alternative routes of administration, such as injectable or transdermal delivery.

The personalized acromegaly treatment and management system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of rare disease treatment, personalized medicine, and digital health. The system's ability to provide real-time monitoring, adaptive dosing, and personalized interventions could lead to improved treatment outcomes, enhanced patient engagement, and reduced healthcare costs.